Cloud Banner

Pharmaceutical

Image

Global Maple Syrup Urine Disease Treatment Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Jul 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Maple Syrup Urine Disease Treatment Market, By Type (Classic MSUD, Intermediate MSUD, Intermittent MSUD, and Others), Treatment Type (Medication and Surgery), Drugs (High-Calorie BCAA-Free Amino Acids, Caloric Supplementation, and Others), Route of Administration (Oral and Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2030.

Maple Syrup Urine Disease Treatment Market

Maple Syrup Urine Disease Treatment Market Analysis and Size

Major factors that are expected to boost the growth of the maple syrup urine disease treatment market in the forecast period are the ongoing clinical trial conducted by several pharmaceutical industries. Furthermore, a rise in the special designation from the regulatory authorities is further anticipated to propel the growth of the maple syrup urine disease treatment market. On the other hand, the inadequate operating revenue prospects for the research and development of targeted therapies by several pharmaceuticals are further projected to impede the growth of the maple syrup urine disease treatment market in the timeline period.

The maple syrup urine disease treatment market is expected to witness market growth at a rate of 11.20% in the forecast period of 2021 to 2028. Data Bridge Market Research report on the maple syrup urine disease treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the demand for disease-specific novel treatments is escalating the growth of the maple syrup urine disease treatment market

Data Bridge Market Research analyses that the Maple Syrup Urine Disease Treatment market, which was USD 8,935 Million in 2022, would rocket up to USD 19,652 Million by 2030 and is expected to undergo a CAGR of 11.20% during the forecast period. This indicates the market value. “Intermittent MSUD” dominates the type segment of the Maple Syrup Urine Disease Treatment market. The growing awareness among healthcare professionals and the general population about maple syrup urine disease (MSUD) drives the demand for effective treatment options. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Maple Syrup Urine Disease Treatment Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Type (Classic MSUD, Intermediate MSUD, Intermittent MSUD, and Others), Treatment Type (Medication and Surgery), Drugs (High-Calorie BCAA-Free Amino Acids, Caloric Supplementation, and Others), Route of Administration (Oral and Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, and Others)

Countries Covered

U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa

Market Players Covered

CENTOGENE AG – Germany, Acer Therapeutics Inc. (U.S.), HemoShear Therapeutics, LLC (U.S.), Recordati SpA – Italy, Jo Mar Laboratories (U.S.), Siddhi Vinayaka Spechem Private Limited (India), Baxter (U.S.), EXOCOBIO (South Korea), Pfizer Inc. (U.S.), Codexis, Inc. (U.S.), Homology Medicines, Inc. (U.S.), Mendel Tijssen BV Netherlands, Biomarin Pharmaceutical Inc. (U.S.), Vitaflo International Ltd. (U.S.), Mead Johnson & Company, LLC  (U.S.), Nutricia Advanced Medical Nutrition (Netherlands), Daiichi Sankyo Company, Limited (Japan), Chiesi Farmaceutici S.p.A. (Italy)

Market Opportunities

  • Research and Development
  • Collaboration and Partnerships

Market Definition

Maple syrup urine disease is also called branched-chain ketoaciduria, which is a hereditary metabolic disorder in which the body is incapable of understanding certain protein building blocks that are known as amino acids properly because of the absence of an enzyme known as BCKDC (branched-chain alpha-keto acid dehydrogenase complex). These enzymes are essential to break down the three branched-chain amino acids (BCAAs) Isoleucine, Leucine, and Valine in the body.

Maple Syrup Urine Disease Treatment Market Dynamics

Drivers

  • Increasing Awareness

Growing awareness among healthcare professionals and the general population about maple syrup urine disease (MSUD) drives the demand for effective treatment options.

  • Technological Advancements:

Advances in diagnostic techniques, genetic testing, and therapeutic interventions improve the management and treatment of MSUD, leading to better patient outcomes.

Opportunities

  • Research and Development

Ongoing research and development activities focused on understanding the disease mechanism and developing innovative treatment approaches present significant opportunities for advancements in MSUD treatment.

  • Collaboration and Partnerships

Collaborations between pharmaceutical companies, research institutions, and advocacy groups can foster innovation, accelerate drug development, and improve access to treatment options for MSUD patients.

Restraints

  • High Treatment Costs

The cost of specialized treatments, including enzyme replacement therapy and dietary management, can be a significant barrier for patients and healthcare systems, limiting access to effective therapies.

Challenges

  • Limited Treatment Options

Currently, a limited number of approved treatment options specifically target MSUD. Developing novel and more effective therapies for MSUD remains a challenge.

Maple syrup urine disease is also called branched-chain ketoaciduria, which is a hereditary metabolic disorder in which the body is incapable of understanding certain protein building blocks that are known as amino acids properly because of the absence of an enzyme known as BCKDC (branched-chain alpha-keto acid dehydrogenase complex). These enzymes are essential to break down the three branched-chain amino acids (BCAAs) Isoleucine, Leucine, and Valine, in the body.

Recent Development

  • In Feb 2022, Relief Therapeutics Holding SA announced a collaboration with Acer Therapeutics and has been granted a new patent by the United States Patent and Trademark Office (USPTO) for specific claims related to ACER-001 (sodium phenylbutyrate). The FDA is currently reviewing Acer Therapeutics' New Drug Application (NDA) for ACER-001 to treat UCDs, with a target action date of June 5, 2022, under the Prescription Drug User Fee Act (PDUFA).

Global Maple Syrup Urine Disease Treatment Market Scope

The maple syrup urine disease treatment market is segmented on the basis of type, treatment type, drugs, route of administration, and end users. The growth among segments helps you analyze niche pockets of development and strategies to approach the market and determine your core application areas and the difference in your target market.

Type

  • Classic MSUD
  • Intermediate MSUD
  • Intermittent MSUD
  • Others.

Treatment Type

  • Medication
  • Surgery

Drug

  • High-calorie BCAA-free amino acids
  • Caloric supplementation
  • Others

Route of Administration

  • Oral
  • Injectable High-calorie BCAA-free amino acids

Route of Administration

  • Hospitals
  • Homecare
  • Specialty clinics
  • Others.

Maple Syrup Urine Disease Treatment Market Regional Analysis/Insights

The maple syrup urine disease treatment market is analyzed, and market size information is provided by country, type, treatment type, drugs, route of administration, and end users, as referenced above.

The countries covered in the maple syrup urine disease treatment market report are the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa.

North America dominates the maple syrup urine disease treatment due to the rise in the incidence of obesity and diabetes. Furthermore, an increase in healthcare expenses and growing alertness regarding metabolic disorders will further boost the growth of maple syrup urine disease treatment in the region during the forecast period.

Asia-Pacific is projected to observe a significant amount of growth during the forecast period of 2023 to 2030 in the maple syrup urine disease treatment due to the swift economic development. Moreover, the Change in lifestyles and the increase in obesity, diabetes, and hypercholesterolemia diseases is further anticipated to propel the growth of the maple syrup urine disease treatment in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

Maple Syrup Urine Disease Treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for Maple Syrup Urine Disease Treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Maple Syrup Urine Disease Treatment market. The data is available for historic period 2010-2020.

Competitive Landscape and Maple Syrup Urine Disease Treatment Market Share Analysis

The Maple Syrup Urine Disease Treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Maple Syrup Urine Disease Treatment market.

Some of the major players operating in the Maple Syrup Urine Disease Treatment market are:

  • CENTOGENE AG - Germany
  • Acer Therapeutics Inc. – U.S.
  • HemoShear Therapeutics, LLC - U.S.
  • Recordati SpA - Italy
  • Jo Mar Laboratories - U.S.
  • Siddhi Vinayaka Spechem Private Limited - India
  • Baxter - U.S.
  • EXOCOBIO - South Korea
  • Pfizer Inc. - U.S.
  • Codexis, Inc. - U.S.
  • Homology Medicines, Inc. - U.S.
  • Mendel Tijssen BV - Netherlands
  • Biomarin Pharmaceutical Inc. - U.S.
  • Vitaflo International Ltd. – U.K.
  • Mead Johnson & Company, LLC - U.S.
  • Nutricia Advanced Medical Nutrition - Netherlands
  • Daiichi Sankyo Company, Limited - Japan
  • Chiesi Farmaceutici S.p.A. - Italy
  • Orphan Europe SARL - France


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Maple Syrup Urine Disease Treatment Market will be worth USD 19,652 Million in 2030.
The Maple Syrup Urine Disease Treatment Market Growth Rate is 11.20% during the forecast period.
The Growing awareness among healthcare professionals and Advances in diagnostic techniques are the Growth Drivers of the Maple Syrup Urine Disease Treatment Market.
The type, treatment type, drugs, route of administration, and end users are the factors on which the Maple Syrup Urine Disease Treatment Market research is based.
The Relief Therapeutics Holding SA announced a collaboration with Acer Therapeutics and has been granted a new patent by the United States Patent and Trademark Office (USPTO) for specific claims related to ACER-001 (sodium phenylbutyrate) are the latest developments in the Maple Syrup Urine Disease Treatment Market
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials